A new antibody treatment is currently in development. Medical researchers behind the innovation claim that the new technology could be effective when it comes to neutralizing new strains of COVID-19, especially the spreading Delta and Lambda variants.
The new monoclonal antibody treatment is one of the medical innovations developed by Celltrion Group, one of the largest firms in the Korean pharmaceutical industry. The company's new regdanvimab or CT-P59 antibody treatment is claimed to have a strong neutralizing effect against new strains of the novel coronavirus.
This could be a major medical breakthrough during the global pandemic, especially since the World Health Organization (WHO) confirmed that the new Delta variant has already infected around 96 countries across the globe, including the United States.
Celltrion's medical scientists explained that they used a clinically relevant dose of the CT-P59 to check its neutralization efficiency.
New Antibody Offers 100% COVID-19 Survival Rate
According to Business Wire's latest report, the new antibody treatment demonstrated a 100% survival rate against COVID-19. However, involved experts did not confirm if it is for the new COVID-19 Delta or Lambda variant.
Although this is the case, the results are still a big deal since it is really higher compared to the placebo group, which offers an almost 0% survival rate against the novel coronavirus.
On the other hand, experts claimed that the new monoclonal antibody treatment could also neutralize other COVID-19 strains, such as the Gamma variant, which was first discovered in Brazil.
"These new data are encouraging and reinforcing our body of both pre-clinical and clinical data," explained Celltrion Healthcare's Head of Medical and Marketing Division Dr. HoUng Kim.
"The Delta variant is a highly transmissible and contagious variant that could prompt further waves of infection around the world. It is important to expand the arsenal of monoclonal antibody therapies that are hoped to remain effective against the emerging COVID-19 variants," he added.
COVID-19 Lambda Variant Already In the US
The Ladders reported that the new COVID-19 Lambda variant is already spreading in the United States. This is an alarming issue since some medical researchers claimed that it is more infectious compared to the Delta strain.
Aside from the United States, it is also spreading in 29 more countries, including Argentina, Brazil, Ecuador, Spain, Germany, Mexico, Chile, and England. COVID-19 Lambda strain was first discovered back in August 2020 in Peru. And now, WHO decided to label this rising COVID-19 strain as a "variant of interest."
For more news updates about COVID-19 and other medical innovations that can neutralize it, always keep your tabs open here at TechTimes.
This article is owned by TechTimes
Written by: Griffin Davis